Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Dr. Reddy’s Launches Debiopharm’s Pamorelin® LA in India for the Treatment of Locally Advanced or Metastatic, Hormone-Dependent Prostate Cancer

December 7, 2012

LAUSANNE, Switzerland, December 7, 2012 /PRNewswire/ –

Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of
companies with a focus on the development of prescription drugs that target unmet medical
needs and companion diagnostics, announces that Dr. Reddy’s Laboratories Ltd. launched
Pamorelin(R) LA in India for the treatment of locally advanced or metastatic,
hormone-dependent prostate cancer on December 3.

Under the terms of the agreement, Dr. Reddy’s acquires exclusive marketing and sales
rights for Pamorelin(R) LA Depot in India. The product is exported in bulk from Debio
Recherche Pharmaceutique (Debio R.P.) to Dr. Reddy’s. Pamorelin(R) LA will be made
available primarily to urologists and oncologists across India.

‘We recognise the need for prostate cancer treatment in India and are thrilled to have
the opportunity to bring Pamorelin(R) LA to Indian patients’, said Rolland-Yves Mauvernay,
President and founder of Debiopharm Group(TM). ‘This major step enables us to implement
our strategy in one of the most important markets in Asia. This is only the logical
continuation to a harmonious working relationship shared with Dr. Reddy’s over the years.’
Dr. Reddy’s and Debiopharm share the same vision to bring high-quality and safe ethical
products to the highest number of patients suffering from serious diseases in India.

About Pamorelin(R) LA (active ingredient: triptorelin)

Triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone
(GnRH). In 1982, Debiopharm signed a licensing agreement for triptorelin with Tulane
University in the US. Debiopharm has then developed three slow-release formulations (1, 3
and 6 months) of triptorelin pamoate. The 1- and 3-month-formulations have been registered
in most countries and are currently available under the names of Trelstar(R) in North
America, Decapeptyl(R) /Pamorelin(R) in Europe and Latin America and from now on, of
Pamorelin(R) in India. The 6-month-formulation has been registered and is available in
Europe and the US.

About Debiopharm Group(TM)

Debiopharm Group(TM) (Debiopharm) is a Swiss-based global biopharmaceutical group of
companies with a focus on the development of prescription drugs that target unmet medical
needs. The group in-licenses, develops and/or co-develops promising biological and small
molecule drug candidates having reached clinical development phases I, II or III, as well
as earlier stage candidates. It develops its products for global registration and maximum
commercial potential. The products are out-licensed to pharmaceutical partners for sales
and marketing. Debiopharm is also active in the field of companion diagnostics with a view
to progressing in the area of personalised medicine. Debiopharm independently funds the
worldwide development of all of its products while providing expertise in pre-clinical and
clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information on Debiopharm Group(TM), please visit:

http://www.debiopharm.com.

About Debio R.P.

Debio Recherche Pharmaceutique (Debio R.P.), based in Martigny (Switzerland), is a
pharmaceutical research, development and production company that has been Swissmedic and
ANVISA (Brazil) certified, as well as inspected and registered by the American Food and
Drug Administration (FDA) and the KFDA (South Korea). Debio R.P. is active in the
discovery, formulation and development of peptides. Debio R.P. forms part of Debiopharm
Group(TM) and employs 130 people, half of whom are university graduates or engineers.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) (Dr. Reddy’s) is an integrated global
pharmaceutical company, committed to providing affordable and innovative medicines for
healthier lives. Through its three businesses – Pharmaceutical Services and Active
Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of
products and services including APIs, custom pharmaceutical services, generics,
biosimilars, differentiated formulations and NCEs. Therapeutic focus is on
gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective
and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela,
S. Africa, Romania, and New Zealand.

For more information, log on to: http://www.drreddys.com [
C:\Users\BSC\Desktop\www.drreddys.com ]

        Debiopharm S.A. Contact
        Maurice Wagner
        Director Corporate Affairs & Communication
        Tel.: +41(0)21-321-01-11
        Fax: +41(0)21-321-01-69
        mwagner@debiopharm.com

        Dr. Reddy' s Contact
        S. Rajan
        rajans@drreddys.com
        Tel.: +91-40-49002445
        Additional Media Contacts
        In London
        Maitland
        Brian Hudspith
        Tel.: +44(0)20-7379-5151
        bhudspith@maitland.co.uk

        In New York
        Russo Partners, LLC
        Martina Schwarzkopf, Ph.D.
        Account Executive
        Tel.: +1-212-845-4292
        Fax: +1-212-845-4260
        martina.schwarzkopf@russopartnersllc.com

        Investors and Financial Analysts:
        Kedar Upadhye
        kedaru@drreddys.com
        Tel.: +91-40-66834297

        Saunak Savla
        saunaks@drreddys.com
        Tel.: +91-40-49002135

        Milan Kalawadia (USA)
        mkalawadia@drreddys.com
        Tel.: +1-908-203-4931

SOURCE The Debiopharm Group


Source: PR Newswire